(Q38610806)

4 September 2017

1 reference

title

Clinical experience with desmopressin: efficacy and safety in central diabetes insipidus and other conditions (English)

1 reference

4 September 2017

1 reference

1 reference

Harris AS

1

1 reference

4 September 2017

language of work or name

English

0 references

publication date

1 April 1989

1 reference

The Journal of Pediatrics

4 September 2017

published in

1 reference

4 September 2017

volume

114

1 reference

4 September 2017

issue

4 Pt 2

1 reference

4 September 2017

page(s)

711-718

1 reference

Effects of DDAVP, a synthetic analogue of vasopressin, in patients with cranial diabetes insipidus

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

DDAVP test for estimation of renal concentrating capacity in infants and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Desmopressin as a treatment for enuresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: reduction in blood product usage with desmopressin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Mechanism of Plasminogen Activator and Factor VIII Increase after Vasoactive Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Intranasal administration of peptides: nasal deposition, biological response, and absorption of desmopressin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Effects of concentration and volume on nasal bioavailability and biological response to desmopressin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Nasal administration of desmopressin by spray and drops

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Recognition of Partial Defects in Antidiuretic Hormone Secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

A Comparison of Plasma Vasopressin Measurements with a Standard Indirect Test in the Differential Diagnosis of Polyuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

1-deamino-8-D-arginine vasopressin in the treatment of central diabetes insipidus in childhood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Management of diabetes insipidus in pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

DDAVP treatment of diabetes insipidus during pregnancy and the post-partum period

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Oral desmopressin in central diabetes insipidus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Desmopressin response of enuretic children. Effects of age and frequency of enuresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Comparison of desmopressin and enuresis alarm for nocturnal enuresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

DDAVP and urine osmolality in refractory enuresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Diurnal Variation of Plasma Vasopressin in Man*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Diurnal anti-diuretic-hormone levels in enuretics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

The use of desmopressin (DDAVP) in nocturnal urinary frequency in the female

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Intranasal DDAVP-test in the study of renal concentrating capacity in children with recurrent urinary tract infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Subcutaneous and intranasal administration of 1-deamino-8-d-arginine vasopressin in the assessment of renal concentration capacity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

DDAVP Test for Assessment of Renal Concentrating Capacity in Infants and Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

DDAVP test for renal concentration capacity. Age-related reference intervals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Water intoxication in infants caused by the urine concentration test with vasopressin analogue (DDAVP)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Neurogenic Diabetes Insipidus: Management with dDAVP (1-Desamino-8-D Arginine Vasopressin)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Management of Nocturnal Enuresis with a Vasopressin Analogue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Treatment of central diabetes insipidus in adults and children with desmopressin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Hormonal and cardiovascular responses to DDAVP in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Antibodies to vasopressin in patients with diabetes insipidus. Implications for diagnosis and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Augmentation by Chlorpropamide of l-Deamino-8-DArginine Vasopressin-Induced Antidiuresis and Stimulation of Renal Medullary Adenylate Cyclase and Accumulation of Adenosine 3′,5′-Monophosphate*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

Antidiuretic responses to hypertonic saline infusion, water deprivation, and a synthetic analogue of vasopressin in patients with hereditary, hypothalamic diabetes insipidus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2889%2980886-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-3476(89)80886-8

1 reference

4 September 2017

1 reference